PERLA RETANA-BROWN: Open Payments
NPI 1518439157 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,285 in 117 payments from 17 companies in 2025. Trend: 2023 $26 · 2024 $190 · 2025 $2,285
Food & beverage: $2,285
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 27 | $594 |
| ANI Pharmaceuticals, Inc. | 18 | $345 |
| UCB, Inc. | 18 | $282 |
| Mallinckrodt Hospital Products Inc. | 18 | $280 |
| ABBVIE INC. | 13 | $239 |
| GENZYME CORPORATION | 2 | $138 |
| GlaxoSmithKline, LLC. | 5 | $93 |
| Aurinia Pharma U.S., Inc. | 4 | $77 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
Products named: PURIFIED CORTROPHIN GEL, Bimzelx, ACTHAR, KRYSTEXXA, RINVOQ, UPLIZNA, BENLYSTA, KEVZARA.
Industry payments across TX — which companies pay providers there.
